Alzamend Neuro, Inc. (Nasdaq: ALZN) announced the completion of its $5 million private placement on June 16, 2025, securing funding months ahead of the originally scheduled October 2025 timeline. The clinical-stage biopharmaceutical company will use the capital to support five Phase II clinical trials of its lead drug candidate AL001 at Massachusetts General Hospital.
The financing was structured through a Securities Purchase & Exchange Agreement with a sophisticated investor, involving up to 500 shares of Series C Convertible Preferred Stock and warrants for common stock purchases. Originally planned as seven monthly tranche closings beginning in April 2025, the investor accelerated the final purchase on June 13, 2025, completing the full $5 million commitment with a five percent discount.
AL001 Clinical Development Program
AL001 represents a novel approach to lithium delivery using patented ionic cocrystal technology. The drug candidate combines lithium with salicylate and L-proline in a therapeutic formulation designed to treat multiple neurological and psychiatric conditions.
The company has outlined an ambitious clinical timeline for its "Lithium in Brain" studies. The first Phase II trial in healthy human subjects was initiated in May 2025, with topline data expected by the end of 2025. A second trial focusing on bipolar disorder treatment is scheduled to commence in the third quarter of 2025. Three additional trials targeting Alzheimer's disease, major depressive disorder, and post-traumatic stress disorder are each planned to begin in the fourth quarter of 2025.
Addressing Significant Patient Population
According to Stephan Jackman, Chief Executive Officer of Alzamend, the financing reflects confidence in the company's mission to address a substantial unmet medical need. "We are grateful to our Investor for providing us the capital to fast-track our clinical programs and ultimately bring hope to patients and families as we pursue breakthrough solutions for the 43+ million American afflicted with Alzheimer's, BD, MDD and PTSD," Jackman stated.
Comprehensive Pipeline Strategy
Beyond AL001, Alzamend's pipeline includes ALZN002, a cell-based therapeutic vaccine using a patented method with mutant-peptide sensitized cells. This second-generation active-immunity approach targets Alzheimer's disease by seeking to restore patients' immunological systems to combat the condition through beta-amyloid removal from the brain.
ALZN002 is designed to address limitations of approved passive immunity antibody products, particularly by reducing dosing frequency and associated costs. Both AL001 and ALZN002 are licensed from the University of South Florida Research Foundation, Inc. under royalty-bearing exclusive worldwide licenses.
The successful completion of this financing positions Alzamend to advance its clinical programs across multiple therapeutic areas, with the potential for additional proceeds if the investor exercises the warrants included in the financing structure.
